Access Program Information
ARQ 092 is being investigated for patients with overgrowth diseases and/or vascular anomalies
with genetic alterations of the PI3K/AKT pathway and may be available for patients who are
ineligible for an ongoing ARQ 092 clinical trial or have other considerations that prevent
access to ARQ 092 through an existing clinical trial.